Company Overview and News

 
Banks Set for Q1 Earnings on Apr 23: ZION, ONB, TCF, BOH

2018-04-20 zacks
Performances of most of the banks that released their first-quarter 2018 results till now were decent. Driven by higher rates and modest improvement in loan balances, banks reported an increase in their net interest income. Also, given the rebound in trading activities during the quarter, trading revenues improved. However, lower mortgage income and dismal investment banking performance adversely impacted overall fee income to some extent.
Upvote Downvote

 
3 Reasons to Add First Financial (FFBC) to Your Portfolio

2018-04-05 zacks
With strong fundamentals and organic growth prospects, First Financial Bancorp. (FFBC - Free Report) appears to be an attractive pick now. In addition, interest rate hikes and improving economy are anticipated to further improve profitability. Analysts seem to be optimistic about the company’s prospects as the stock is witnessing upward estimate revisions. Over the past 60 days, the Zacks Consensus Estimate for the current year has risen nearly 1.
Upvote Downvote

 
5 Reasons to Make Fifth Third (FITB) Part of Your Portfolio

2018-04-05 zacks
Fifth Third Bancorp (FITB - Free Report) is a promising stock now due to its diligent efforts to enhance profitability through Project North Star initiatives. Also, the company’s organic and inorganic growth strategies make it well poised for future endeavors. Further, earnings growth prospects and favorable valuation make it an attractive pick.
Upvote Downvote

 
HBAN or TCF: Which Bank Stock Will Provide Better Returns?

2018-04-04 zacks
The U.S. banking sector has been the center of attraction for quite some time now due to the favorable turn of events since Trump took office. Moreover, continual rise in interest rates and lower commercial tax rate are likely to further boost profitability of the banks.
Upvote Downvote

 
TCF Financial started at neutral with $24 stock price target at UBS

2018-03-22 marketwatch
A probe by the Manhattan district attorney into Newsweek Media Group, including its ad practices and loans, has widened to look at ties to a California bible college.
Upvote Downvote

1
TCF Financial: A Potential Takeover Target?

2018-02-15 seekingalpha
More importantly, the bank increased its dividend by 100%, from $0.30 per share to $0.60 per share.
Upvote Downvote

 
TCB / TCF Financial Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-09 fintel.io
TCF Financial Corp. (NYSE:TCB) has 374 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 154,498,730 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, State Street Corp, Tcf Financial Corp, JP Morgan Chase & Co, FMR LLC / Fidelity, Wedge Capital Management L L P/nc, Citadel Advisors Llc, and Hotchkis & Wiley Capital Management Llc.
Upvote Downvote

 
Preferred Stocks And Baby Bonds: Redeemed Issues

2018-02-07 seekingalpha
This update is not done in the most timely manner, but some of you may still find it useful.
Upvote Downvote

 
Top Dividend Raises And Cuts For January 2018

2018-02-06 seekingalpha
Dividend growth investing is a popular model followed by the investing community to build assets. Companies which not only pay dividends, but raise them year after year have been shown to perform better overall for investor returns.
Upvote Downvote

 
TCF Financial (TCF) Stock Down 1.68% on Q4 Earnings Miss

2018-01-31 zacks
Shares of TCF Financial Corporation (TCF - Free Report) declined 1.68% in single-day trading following the fourth-quarter 2017 earnings release on Jan 30, before the market opened. The company reported adjusted earnings per share of 33 cents, lagging the Zacks Consensus Estimate of 35 cents. However, the figure compared favorably with the prior-year quarter figure of 27 cents. Elevated expenses and provisions were on the downside.
Upvote Downvote

 
TCF Financial's (TCF) CEO Craig Dahl on Q4 2017 Results - Earnings Call Transcript

2018-01-30 seekingalpha
Good morning, and welcome to TCF's 2017 Fourth Quarter Earnings Call. My name is Jamie and I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] Please note today's conference call is being recorded.
Upvote Downvote

 
TCF Financial Corporation 2017 Q4 - Results - Earnings Call Slides

2018-01-30 seekingalpha
The following slide deck was published by TCF Financial Corporation in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
10 banks consumers complain about the most

2018-01-09 cnbc
They compete with cable companies, airlines and drug companies as being some of the most disliked.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...